Chlamydia MIF IgM. Performance Characteristics. Product Code IF1250M Rev. I. Not for Distribution in the United States
|
|
- Damon Payne
- 5 years ago
- Views:
Transcription
1 Product Code IF1250M Rev. I Performance Characteristics Not for Distribution in the United States EXPECTED VALUES Community Acquired Pneumonia Population Two outside investigators assessed the Focus Chlamydia MIF IgM and the Focus Chlamydia MIF IgG ("Focus MIFs") with a total of 144 community acquired pneumonia patients. 141 of the 144 were sequentially selected, and three patients were selected because they were PCR positive for C. pneumoniae. Each patient was an adult outpatient, and their pneumonia was confirmed with a positive chest x-ray. Serum samples were drawn twice, the first serum was drawn 2 weeks or more postonset of symptoms, and the second serum was drawn 3 to 6 weeks after the first. Each patient was tested for C. pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae and Streptococcus pneumoniae. C. pneumoniae testing included culture, PCR, and reference MIFs (IgG and IgM) from a university in the Pacific Northwest. Legionella pneumophila testing included serology (polyvalent antibody), urinary antigen and PCR. Mycoplasma pneumoniae testing included culture, PCR and serology (IgG and IgM). Streptococcus pneumoniae testing included urinary antigen. The observed prevalences and the hypothetical predictive values for the population are shown in the tables below. Community Acquired Pneumonia Outpatients Prevalence vs. Pathogen Prevalence C. pneumoniae (presumed and possible acute) 12.8% C. pneumoniae (presumed acute) 3.5% C. pneumoniae (possible acute) 9.2% Undifferentiated Chlamydia (presumed acute) 0.7% Legionella pneumophila 2.8% Mycoplasma pneumoniae 13.5% Streptococcus pneumoniae 8.5% Unidentified Pathogen, including C. trachomatis (past infection) C. trachomatis (possible acute) C. psittaci (past infection) 61.0% PERFORMANCE CHARACTERISTICS Reactivity with Community Acquired Pneumonia Patients Two outside investigators evaluated the Focus MIF IgM and IgG (Focus MIFs) reactivity with a total of 144 community acquired pneumonia (CAP) patients. The patients and test methods are described in the EXPECTED VALUES section (above). Focus MIF reactivity was calculated for the IgM MIF alone, the IgG MIF alone and the combined reactivity of both of the Focus MIF IgM and Focus MIF IgG ("Combined Focus MIFs"). Predictive values are based on the estimated reactivity of both of the Focus MIF IgM and Focus MIF IgG combined ("Combined Focus MIFs") for C. pneumoniae: 99.8% (85/86) specificity with the combined Focus MIFs, 87.5% (7/8) sensitivity with the combined Focus MIFs, 37.5% (3/8) sensitivity with the Focus MIF IgM, and 62.5% (5/8) sensitivity with the Focus MIF IgG. 99.8% (85/86) specificity with the Focus MIF IgG. Prevalence vs. Hypothetical Predictive Values for C. pneumoniae Pos Prev Combined IgM IgG % PPV % NPV % PPV % NPV % PPV % NPV %
2 Page 2 The unidentified pathogen pneumonia group (negative for all tests performed) included 86 of 144 patients. Focus MIF reactivity for C. pneumoniae with patients infected with unidentified pathogens was as follows: 99.8% (85/86) specificity with the combined Focus MIFs, 99.8% (85/86) specificity with the Focus MIF IgG. Focus MIF reactivity for C. trachomatis with patients infected with unidentified pathogens was as follows: 100% (86/86) specificity with the combined Focus MIFs, 100% (86/86) specificity with the Focus MIF IgG (there were two past C. trachomatis infections detected). The C. pneumoniae presumed acute pneumonia group (PCR positive, and/or IgM reference MIF positive, and/or reference MIF IgG with a 4-fold rise) included 8 of 144 patients. Focus MIF reactivity for C. pneumoniae with presumed acute C. pneumoniae patients was as follows: 87.5% (7/8)* sensitivity with the combined Focus MIFs, 37.5% (3/8) sensitivity with the Focus MIF IgM, and 62.5% (5/8)* sensitivity with the Focus MIF IgG. * The one Focus C. pneumoniae negative sample was detected by the Focus IgG MIF as an undifferentiated Chlamydia presumed acute infection (C. trachomatis positive and C. psittaci positve). Focus MIF reactivity for C. trachomatis with presumed acute C. pneumoniae patients was as follows: 100% (7/7)** specificity with the combined Focus MIFs, 100% (8/8) specificity with the Focus MIF IgM, and 100% (7/7)** specificity with the Focus MIF IgG. ** Excludes one Focus C. pneumoniae negative sample that was detected by the Focus IgG MIF as an undifferentiated Chlamydia presumed acute infection (C. trachomatis positive and C. psittaci positve). The C. pneumoniae possible acute pneumonia group (reference MIF IgM negative, culture negative, PCR negative, and with a reference MIF IgG endpoint of 1:512 or greater) included 13 of 144 patients. Focus MIF reactivity for C. pneumoniae with possible acute C. pneumoniae patients was as follows: 100% (13/13) agreement between the Focus MIF IgM and reference IgM MIF (both IgM MIFs were negative), and 23.1% (3/13) sensitivity with the Focus MIF IgG. The presumed Legionella pneumophila pneumonia group (Legionella sero-positive) included 3 of 144 patients. Focus MIF reactivity for C. pneumoniae with presumed Legionella pneumophila patients was as follows: 100% (3/3) specificity with the combined Focus MIFs, 100% (3/3) specificity with the Focus MIF IgM, and 100% (3/3) specificity with the Focus MIF IgG. Focus MIF reactivity for C. trachomatis with presumed Legionella pneumophila patients was as follows: 100% (3/3) specificity with the combined Focus MIFs, 100% (3/3) specificity with the Focus MIF IgM, and 100% (3/3) specificity with the Focus MIF IgG. The presumed Mycoplasma pneumoniae pneumonia group (Mycoplasma IgM positive and/or Mycoplasma IgG with a 4-fold rise) included 19 of 144 patients. One of the 19 patients was positive for both Mycoplasma pneumoniae and Streptococcus pneumoniae. Focus MIF reactivity for C. pneumoniae with presumed Mycoplasma pneumoniae patients was as follows: 100% (19/19) specificity with the combined Focus MIFs, 100% (19/19) specificity with the Focus MIF IgM, and 100% (19/19) specificity with the Focus MIF IgG. Focus MIF reactivity for C. trachomatis with presumed Mycoplasma pneumoniae patients was as follows: 100% (19/19) specificity with the combined Focus MIFs, 100% (19/19) specificity with the Focus MIF IgM, and 100% (19/19) specificity with the Focus MIF IgG. The presumed Streptococcus pneumoniae pneumonia group (Streptococcus pneumoniae urinary antigen positive) included 12 of 144 patients. One of the 12 patients was positive for both Mycoplasma pneumoniae and Streptococcus pneumoniae. Focus MIF reactivity for C. pneumoniae with presumed Streptococcus pneumoniae patients was as follows: 100% (12/12) specificity with the combined Focus MIFs, 100% (12/12) specificity with the Focus MIF IgM, and 100% (12/12) specificity with the Focus MIF IgG. Focus MIF reactivity for C. trachomatis with presumed Streptococcus pneumoniae patients was as follows: 100% (12/12) specificity with the combined Focus MIFs, 100% (12/12) specificity with the Focus MIF IgM, and 100% (12/12) specificity with the Focus MIF IgG.
3 Page 3 Focus MIF % C. pneumoniae Positive C. pneumo L. pneumo M. pneumo Pathogen S. pneumo IgM IgG Combined Unidentified Focus MIF Reactivity to C. pneumoniae with Community Acquired Pneumonia Patients Community Acquired Pneumonia Patients (C. pneumoniae) Focus MIF % C. pneumoniae Positive IgM IgG Combined (IgG+IgM) Unidentified Pathogen 0.0% (0/86) 1.2% (1/86) 1.2% (1/86) 95%CI % 95%CI % C. pneumoniae (Presumed Acute) 37.5% (3/8) 62.5% (5/8) 87.5% (7/8) 95%CI % 95%CI % 95%CI % C. pneumoniae (Possible Acute) 0.0% (0/13) 23.1% (3/13) 23.1% (3/13) 95%CI % 95%CI % C. pneumoniae (Possible Acute) & L. pneumophila 75.0% (3/4)* 95%CI % 75.0% (3/4)* 95%CI % Legionella pneumophila Mycoplasma pneumoniae Streptococcus pneumoniae * 2/3 of the Focus IgG positives were possible acutes ( 512), and the third positive was a presumed acute ( 4X rise). Includes one sample that was positive for Streptococcus pneumoniae and Mycoplasma pneumoniae The one Focus IgG that was C pneumoniae positive in the unidentified pathogen group was a presumed acute ( 4X rise). Community Acquired Pneumonia Patients Focus MIF C. trachomatis % Positive IgM IgG Combined (IgG+IgM) C. pneumoniae (Presumed Acute) C. pneumoniae (Possible Acute) C. pneumoniae (Possible Acute) & L. pneumophila Legionella pneumophila Mycoplasma pneumoniae Streptococcus pneumoniae Unidentified Pathogen 0.0% (0/8) 95%CI % 0.0% (0/13) 0.0% (0/86) 0.0% (0/7)* 95%CI % 0.0% (0/13) 0.0% (0/86) 0.0% (0/7) 95%CI % 0.0% (0/13) 0.0% (0/86) * Excludes one presumed acute C. pneumoniae sample that was an undifferentiated Chlamydia positive (C. trachomatis and C. psittaci positive) in the Focus MIF which may have not been identified in the reference MIF. Two past C. trachomatis infections were detected in each of the possible C pneumoniae infection group and the unidentified pathogen group.
4 Page 4 Chlamydia pneumoniae Culture/PCR Positives An outside investigator evaluated the test's reactivity with 98 sera from 27 patients that exhibited symptoms of acute respiratory disease. Each patient was Chlamydia pneumoniae culture and/or PCR positive population. The Focus IgM MIF was C. pneumoniae positive for 68.4% (67/98) of sera, and C. pneumoniae positive for 88.9% (24/27) of patients. The Focus IgM MIF was C. trachomatis positive for 0.0% (0/98) of sera, and C. trachomatis positive for 0.0% (0/27) of patients. C. pneumoniae Culture/PCR Positives C. pneumoniae culture/pcr positives (reactivity by sera) 68.4% (67/98) 95% CI % 0.0% (0/98) 95% CI % C. pneumoniae culture/pcr positives (reactivity by patient) 88.9% (24/27) 95% CI % 0.0% (0/27) 95% CI % * Sera from early draws (2-3 weeks from onset) from 2 patients were undifferentiated Chlamydia positive (positive on all 3 antigen spots) by the Focus assay. C. trachomatis Culture Positives An outside investigator evaluated the test's cross-reactivity with 75 sera from 29 patients that were C. trachomatis culture positive. Most patients (27/29) were infants. 35 sera were C. trachomatis seropositive, including 2 having endpoints of 1:1280. The Focus IgM MIF was C. pneumoniae positive with 1.3% (1/75) of sera, 3.5% (1/29) of patients, and 0.0% (0/35) of reference MIF C. trachomatis sero-positives. The Focus IgM MIF was C. trachomatis positive with 46.7% (35/75) of sera, and 75.9% (22/29) of patients. Reactivity with C. trachomatis Culture Positives C. trachomatis culture positives (reactivity by sera) 1.3% (1/75) 95% CI % 46.7% (35/75) 95% CI % C. trachomatis culture positives (reactivity by patient) 3.5% (1/29) 95% CI % 75.9% (22/29) 95% CI % Reactivity with C. psittaci Seropositives An outside investigator evaluated the Focus MIF IgM's cross-reactivity with 42 sera from 19 Chlamydia psittaci sero-positive patients. All of the patients were seropositive by Chlamydia complement fixation, and sero-positive by a MIF (IgM and/or IgG) from a university located in the Pacific Northwest United States, and each patient had epidemiological evidence of Chlamydia psittaci infection. 16 of the 19 patients were drawn more than once. The Focus IgM MIF was C. pneumoniae positive with 10.5% (2/19) of the patients, and 11.9% (5/42) of the sera. The Focus IgM MIF was C. trachomatis positive with was 10.5% (2/19) of the patients, and 7.1% (3/42) of the sera. The Focus IgM MIF was C. psittaci positive with 57.9% (11/19) of the patients, and 52.4% (22/42) of the sera. Reactivity with C. psittaci Seropositives 11.9% (5/42)* 7.1% (3/42)** C. psittaci seropositives (reactivity by sera) 95% CI % 95% CI % C. psittaci seropositives (reactivity by 10.5% (2/19) 10.5% (2/19) patient) 95% CI % 95% CI % * 4/5 of the positives were undifferentiated Chlamydia positives (positive with both of the C. psittaci and C. pneumoniae antigen spots). ** 3/3 of the positives were undifferentiated Chlamydia positives (positive with two or more of the antigen spots: the C. trachomatis and either the C. psittaci and/or C. pneumoniae antigen spots). Reactivity with Blood Donors An outside investigator evaluated the test's reactivity with sera from 100 blood donors. The Focus IgM MIF was C. pneumoniae positive with 2.0% (2/100) and C. trachomatis positive for 1.0% (1/100) of blood donors. The C. pneumoniae and C. trachomatis results both include one serum that was an undifferentiated Chlamydia positive (positive with the C trachomatis and C. pneumoniae antigen spots by the Focus MIF). Reactivity with Blood Donors (n = 100) Blood Donors 2.0% (2/100)* 95% CI % 1.0% (1/100)* 95% CI % * Includes 1 serum that was an undifferentiated Chlamydia positive (positive with the C trachomatis and C. pneumoniae antigen spots) by the Focus assay.
5 Page 5 Cross-reactivity with Microbes Causing Similar Symptoms An investigator evaluated the test's reactivity with Mycoplasma pneumoniae IgM sero-positives and Legionella pneumophila sero-positives The Focus IgM MIF was C. pneumoniae positive with 0.0% (0/10) of M. pneumoniae IgM sero-positives, and 0.0% (0/5) of L. pneumophila sero-positives. The Focus IgM MIF was also C. trachomatis negative with all of the M. pneumoniae samples and all of the L. pneumophila samples. Cross-reactivity with Microbes Causing Similar Symptoms Mycoplasma pneumoniae IgM sero-positives 0.0% (0/10) 95% CI % Legionella pneumophila sero-positives 0.0% (0/5) 0.0% (0/10) 95% CI % 0.0% (0/5) Cross-reactivity with Common Viruses An investigator evaluated the test's reactivity with EBV (Viral Capsid Antigen) IgM positives, CMV IgM positives and Influenzae A IgG positives. The Focus IgM MIF was C. pneumoniae positive with of EBV (Viral Capsid Antigen) IgM positives, 0.0% (0/11) of CMV IgM positives, and 0.0% (0/5) of Influenzae A IgG positives. The Focus IgM MIF was also C. trachomatis negative with all of the EBV, CMV and Influenzae A samples. Cross-reactivity with Common Viruses EBV VCA IgMo seropositives 95% CI % CMV IgM seropositives 0.0% (0/11) 95% CI % Influenzae A IgG seropositives 0.0% (0/5) 95% CI % 0.0% (0/11) 95% CI % 0.0% (0/5) Interference with Rheumatoid Factor & Anti-Nuclear Antibody An investigator evaluated interference with six rheumatoid factor sera and six anti-nuclear antibody sero-positives. The Focus IgM MIF was C. pneumoniae positive with 0.0% (0/6) of rheumatoid factor sera, and 0.0% (0/6) of anti-nuclear antibody sero-positives. The Focus IgM MIF was also C. trachomatis negative with all of the rheumatoid factor sera, and all of the anti-nuclear antibody sera. Interference with Rheumatoid Factor & Anti-Nuclear Antibody % Positives by sera 0.0% (0/6) 0.0% (0/6) % Positives by patient 0.0% (0/6) 0.0% (0/6) IgG removal by IgM Pretreatment Diluent An investigator evaluated IgG removal by pretreatment diluent using six samples with IgG 700mg/dL. IgG concentration was determined by nephelometry before and after pretreatment. The Pretreatment reduced IgG at least 100-fold on all six samples. Inter-assay Reproducibility An investigator evaluated inter-assay reproducibility by testing 24 sera endpointed with all three antigens, in 3 runs, with one run on three separate days. 99% (213/216) of endpoints were within 2-fold dilution among all repeated runs. Inter-lot Reproducibility An investigator evaluated inter-lot reproducibility by testing 15 sera endpointed with all three antigens with three different lots of slides. 100% (135/135) of endpoints were within 2-fold dilution among all repeated runs. Inter-laboratory Reproducibility Two off-site investigators evaluated inter-laboratory reproducibility by testing 15 sera endpointed with all three antigens. 98% (265/270) of endpoints were within 2- fold dilution among all 6 runs. AUTHORIZED REPRESENTATIVE mdi Europa GmbH, Langenhagener Str. 71, Langenhagen-Hannover, Germany ORDERING INFORMATION Telephone: (562) (International) Fax: (562) PC.IF1250M Rev. I Date written: 27 Jan 2011 TECHNICAL ASSISTANCE Telephone: (562) (International) Fax: (562) Visit our web site at: Cypress, California 90630, U.S.A
Chlamydia MIF IgG. Performance Characteristics. Product Code IF1250G Rev. J. Not for Distribution in the United States
Product Code IF1250G Rev. J Performance Characteristics Not for Distribution in the United States EXPECTED VALUES Community Acquired Pneumonia Population Two outside investigators assessed the Focus Chlamydia
More informationUSA Product Listing. Serology Diagnostic Products
USA Product Listing Serology Diagnostic Products Focus Diagnostics recognizes your testing needs because we identify and evaluate trends in diagnostic testing. The products listed in this brochure were
More informationEvaluation of the Oxoid Xpect Legionella test kit for Detection of Legionella
JCM Accepts, published online ahead of print on 6 May 2009 J. Clin. Microbiol. doi:10.1128/jcm.00397-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationReceived 3 August 2005/Returned for modification 13 September 2005/Accepted 13 January 2006
CLINICAL AND VACCINE IMMUNOLOGY, Mar. 2006, p. 361 364 Vol. 13, No. 3 1556-6811/06/$08.00 0 doi:10.1128/cvi.13.3.361 364.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Evaluation
More informationJ07 Titer dynamics, complement fixation test and neutralization tests
avllm0421c (spring 2017) J07 Titer dynamics, complement fixation test and neutralization tests Outline titer, antibody titer dynamics complement, complement fixation reaction neutralization tests 2/35
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Blum CA, Nigro N, Briel M, et al. Adjunct prednisone
More informationELISA Range. VIROTECH Diagnostics GmbH. Lot independent. Reagent. System. IgG-Conjugate. Substrate. IgM-Conjugate. Washing Solution.
Quelle: www.fotolia.com ELISA Range IgG-Conjugate IgM-Conjugate IgA-Conjugate Lot independent Reagent System Stop Solution Substrate Washing Solution Serum Dilution Dilution Buffer Incubation Time Cerebrospinal
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of Accreditation 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK National Infection Service, Public Health England Colindale 61 Colindale Avenue London NW9 5EQ Contact: Dr Sanjiv
More informationCommunity Acquired Pneumonia. Abdullah Alharbi, MD, FCCP
Community Acquired Pneumonia Abdullah Alharbi, MD, FCCP A 68 y/ male presented to the ED with SOB and productive coughing for 2 days. Reports poor oral intake since onset due to nausea and intermittent
More informationTest Requested Specimen Ordering Recommendations
Microbiology Essentials Culture and Sensitivity (C&S) Urine C&S Catheter Surgical (excluding kidney aspirates) Voided Requisition requirements o Specific method of collection MUST be indicated o Indicate
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Issue No: 001 24 September 2018 Department of Microbiology Longfleet Road Poole Dorset BH15 2JB Contact: Andrew Barber Tel: +44 (0)202 448585 E-Mail: andy.barber@poole.nhs.uk Website: www.poole.nhs.uk
More informationDEPARTMENT OF MICROBIOLOGY IMPORTANT NOTICE TO USERS Turnaround Times (TATs) for Microbiology Investigations
Dear User, ISSUE: M008 DEPARTMENT OF MICROBIOLOGY IMPORTANT NOTICE TO USERS Turnaround Times (TATs) for Microbiology Investigations In order to comply with national quality guidance and as part of our
More informationPart II Serology Caroline Bax BW.indd 55 Caroline Bax BW.indd : :17
Part II Serology part II Chapter 4 Comparison of serological assays for detection of Chlamydia trachomatis antibodies in different groups of obstetrical and gynaecological patients C.J. Bax J.A.E.M. Mutsaers
More informationMycoplasma pneumoniae IgG ELISA Kit
Mycoplasma pneumoniae IgG ELISA Kit Catalog Number KA2260 96 assays Version: 01 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle
More informationIP Lab Webinar 8/23/2012
2 What Infection Preventionists need to know about the Laboratory Anne Maher, MS, M(ASCP), CIC Richard VanEnk PhD, CIC 1 Objectives Describe what the laboratory can do for you; common laboratory tests
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Royal Liverpool & Broadgreen University Hospitals NHS Trust Department of Virology Liverpool Clinical Laboratories Royal Liverpool and Broadgreen
More informationToshio Kishimoto*, Shuji Ando, Kei Numazaki 1, Kazunobu Ouchi 2, Tsutomu Yamazaki 3, and Chikara Nakahama 4
Jpn. J. Infect. Dis., 62, 260-264, 2009 Original Article Assay of Chlamydia pneumoniae-specific IgM Antibodies by ELISA Method---Reduction of Non-Specific Reaction and Resetting of Serological Criteria
More informationMENU PRODUCT MOLECULAR. International Product Listing. Simplexa Molecular Kits Integrated Cycler Molecular Reagents and Primer Pairs
International Product Listing MOLECULAR PRODUCT MENU Simplexa Molecular Kits Integrated Cycler Molecular Reagents and Primer Pairs Products are not intended for donor screening. Simplexa Molecular Kits
More informationSupplementary Online Content
Supplementary Online Content Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory
More informationHistoplasma DxSelect. Enzyme-linked Immunosorbent Assay (ELISA) Product Code EL1700. Rev. E
Enzyme-linked Immunosorbent Assay (ELISA) Product Code EL1700 Rev. E Enzyme-linked immunosorbent assay for the qualitative detection of human antibodies to Histoplasma capsulatum var. capsulatum Within
More informationCHEMILUMINESCENCE ENZYME IMMUNOASSAY (CLIA) Toxoplasma IgG. Cat # (20-25 C Room temp.) Volume
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Clinical Microbiology QMC Campus Derby Road Nottingham NG7 2UH Contact: Jil Bowskill Tel: +44 (0) 1905 760192 Ext 30659 E-Mail: jilean.bowskill@nuh.nhs.uk
More informationIdentification of Microbes Lecture: 12
Diagnostic Microbiology Identification of Microbes Lecture: 12 Electron Microscopy 106 virus particles per ml required for visualization, 50,000-60,000 magnification normally used. Viruses may be detected
More informationDesign Verification. Form:
Design Verification SYPHILIS TPHA liquid CONTENTS 1 Function... 2 2 Sensitivity... 2 Preparation of Serum Control Panel... 2 Kit Controls Positive and Negative... 3 3 Traceability... 3 4 Specificity and
More informationChlamydia MIF IgA (OUS)
(OUS) REF IF1250A Rev. S Micro-immunofluorescent assay (MIF) for the detection of human serum IgA antibodies to Chlamydia pneumoniae and Chlamydia trachomatis infections This package insert is for export
More informationHealth Board Logo. Post SARS Outbreak Surveillance. Report of possible or probable cases (Form version 1) February 11 th 2004
Post SARS Outbreak Surveillance Report of possible or probable cases (Form version 1) February 11 th 2004 This form is to be used for persons who fit the surveillance case definition of possible or probable
More informationSimultaneous and Rapid Detection of Causative Pathogens in Community-acquired Pneumonia by Real-time PCR (1167)
From the Japanese Association of Medical Sciences The Japanese Association for Infectious Diseases Simultaneous and Rapid Detection of Causative Pathogens in Community-acquired Pneumonia by Real-time PCR
More informationReQuest HSV Type 1 Specific IgG
01-410 96 Test Set For Prescription Use Only Intended Use: For In Vitro Diagnostic Use Only. The ReQuest HSV Type 1 Specific IgG assay is an enzyme-linked immunosorbent assay (ELISA) intended for the qualitative
More informationInstitut Pasteur de Nouvelle Calédonie 12 / 12 / 02
Evaluation of reagents for the serological diagnosis of Dengue EPINET II Workshop (Noumea, March, 2002) Alain BERLIOZ-ARTHAUD, New Caledonia Pasteur Institute, B.P. 61, 98845 Noumea, NC aberlioz@pasteur.nc
More informationChlamydia Trachomatis IgM ELISA Kit
Chlamydia Trachomatis IgM ELISA Kit Catalog Number KA0960 96 assays Version: 03 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle
More informationJAJ International, Inc./LuSys Laboratories, Inc.
JAJ International, Inc./LuSys Laboratories, Inc. 10054 Mesa Ridge Court, Suite #120 San Diego, California 92121 USA Tel: 1(858) 866-0788, Fax: 1(858) 866-1688 Email: info@jajinternational.com Website:
More informationCorporate Medical Policy
Corporate Medical Policy Identification of Microorganisms Using Nucleic Acid Probes File Name: Origination: Last CAP Review: Next CAP Review: Last Review: identification_of_microorganisms_using_nucleic_acid_probes
More informationX/01/$ DOI: /CDLI Received 6 November 2000/Returned for modification 6 February 2001/Accepted 27 February 2001
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, May 2001, p. 588 592 Vol. 8, No. 3 1071-412X/01/$04.00 0 DOI: 10.1128/CDLI.8.3.588 592.2001 Comparison of Two Commercial Microimmunofluorescence Kits and
More informationTest Definition: FMCPS Meningoencephalitis Comprehensive Panel (Serum)
Reporting Title: Meningoencephalitis Comp Panel, S Performing Location: Focus Diagnostics, Specimen Requirements: Draw blood in a plain, red-top tube(s). (Serum gel tube is acceptable.) Spin down and send
More informationAccredited entity according to ČSN EN ISO 15189:2013 Laboratoře Mikrochem a.s. Mikrochem Laboratories Nezvalova 984/2, Hodolany, Olomouc
Medical laboratory locations: 1. Olomouc Nezvalova 984/2, 779 00 Olomouc 2. Přerov Čechova 8, 750 02 Přerov 3. Šumperk Nerudova 34, 787 01 Šumperk 4. Valašské Meziříčí Vsetínská 854, 757 01 Valašské Meziříčí
More informationChain of Infection Agent Mode of transmission Contact (direct, indirect, droplet spread) Airborne Common-vehicle spread Host
Goals Microbiology of Healthcare-associated Infections William A. Rutala, Ph.D., M.P.H. Director, Statewide Program for Infection Control and Epidemiology and Research Professor of Medicine, University
More informationLaboratory Evidence of Human Viral and Selected Non-viral Infections in Canada
Canada Communicable Disease Report ISSN 1188-4169 Date of publication: October 1998 Volume 24S7 Supplement Laboratory Evidence of Human Viral and Selected Non-viral Infections in Canada 1989 to 1996 Our
More informationEarly February Surveillance of severe atypical pneumonia in Hospital Authority in Hong Kong. Initiate contacts in Guangdong
SARS: Aetiology JSM Peiris The University of Hong Kong & Queen Mary Hospital WHO SARS Laboratory Network Hospital Authority and Department of Health, HK Early February 2003 Surveillance of severe atypical
More informationHIV AND LUNG HEALTH. Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital
HIV AND LUNG HEALTH Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital Introduction HIV infection exerts multiple effects on pulmonary immune responses: Generalised state of immune
More informationReQuest EB VCA IgM L
01-480 96-Test Set For in Vitro Diagnostic Use Only Intended Use: For the qualitative detection of human IgM antibodies to Epstein-Barr (EB) viral capsid antigen (VCA) in human serum by enzyme immunoassay,
More informationpoint-of-care test (POCT) Definition: an analytical or diagnostic test undertaken in a setting distinct from a normal hospital or non-hospital
point-of-care test (POCT) Definition: an analytical or diagnostic test undertaken in a setting distinct from a normal hospital or non-hospital laboratory performed by a health care professional or non-medical
More informationReceived 24 November 1997/Returned for modification 11 February 1998/Accepted 6 April 1998
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, July 1998, p. 486 490 Vol. 5, No. 4 1071-412X/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Seroprevalence of Antibodies
More informationDevelopment and evaluation of user-developed protocols for bacterial respiratory pathogens leveraging the snap-load-go workflow of BD MAX TM
PAMM FOUNDATION LABORATORY FOR PATHOLOGY AND MEDICAL MICROBIOLOGY Development and evaluation of user-developed protocols for bacterial respiratory pathogens leveraging the snap-load-go workflow of BD MAX
More informationTest Menu. Infectious Diseases Laboratory. Division of Infectious Diseases Department of Medicine
Test Menu Infectious Diseases Laboratory Division of Infectious Diseases Department of Medicine July 2017 1 Atypical Pneumonia PCR Panel (APP)* The APP is an in-house developed, real-time (RT) PCR assay,
More informationCommunity-acquired pneumonia (CAP)
Community-acquired pneumonia (CAP) Keith F Barker, MD GlaxoSmithKline 1 CAP: Key issues Definitions and patient population Use of prior antibiotics Microbiologically Evaluable population Efficacy endpoints
More informationUpper...and Lower Respiratory Tract Infections
Upper...and Lower Respiratory Tract Infections Robin Jump, MD, PhD Cleveland Geriatric Research Education and Clinical Center (GRECC) Louis Stokes Cleveland VA Medical Center Case Western Reserve University
More informationChlamydial pneumonia in children requiring hospitalization: effect of mixed infection on clinical outcome
J Microbiol Immunol Infect 2005;38:117-122 Tsai et al Chlamydial pneumonia in children requiring hospitalization: effect of mixed infection on clinical outcome Ming-Han Tsai 1, Yhu-Chering Huang 1, Chih-Jung
More informationPNEUMONIA IN A PRESUMED IMMUNOCOMPETENT PATIENT
Dr Marie Bruyneel and Deborah Konopnicki BVIKM/SBMIC November 8th, 2012 PNEUMONIA IN A PRESUMED IMMUNOCOMPETENT PATIENT Men, 54 years Emergency room on end october 2009 Sent by his family doctor for Influenza
More informationMICROWELL ELISA Measles IgM Catalog #
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationChlamydia pneumoniae: a new opportunistic infectious agent in AIDS?
ORIGINAL ARTICLE Chlamydia pneumoniae: a new opportunistic infectious agent in AIDS? Rosa Monno 1, Emilia Leone 1, Paolo Maggi 2, Giovanni Buccoliero 2, Maria A. valenza 1 and Gioacchino Angarano 2 1Institute
More informationSee external label 2 C-8 C 96 tests CHEMILUMINESCENCE. CMV IgG. Cat # Step (20-25 C Room temp.) Volume
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationHerpeSelect 1 ELISA IgG (English)
(English) REF EL0910G-5 (480 Determinations) Rev. I Enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of human IgG class antibodies to HSV-1 For in vitro Diagnostic Use INTENDED USE
More informationMicrobiology of Atypical Pneumonia. Dr. Mohamed Medhat Ali
Microbiology of Atypical Pneumonia Dr. Mohamed Medhat Ali Pneumonia P n e u m o n i a i s a n infection of the lungs that can be caused by viruses, bacteria, and fungi. Atypical! Pneumonia Symptoms. X-ray
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Microbiology Department Contact: Dr David Ashburn Zone 3 Raigmore Hospital Tel: +44 (0) 1463 704108 Old Perth Road Fax: +44 (0) 1463 705648
More informationStudy objective: To investigate the clinical presentation of community-acquired Chlamydia
Clinical Presentation of Community- Acquired Chlamydia pneumoniae Pneumonia in Adults* Naoyuki Miyashita, MD, PhD; Hiroshi Fukano, MD; Niro Okimoto, MD, PhD, FCCP; Hiroki Hara, MD, PhD, FCCP; Koichiro
More informationBrrrr, It s Cold In Here
Brrrr, It s Cold In Here Kate Grogan, MD Transfusion Medicine Fellow Physician, BloodworksNW 4/24/15 Patient 20 year old female Viral illness Presents one week later with severe hemolysis Hgb 5.6 Increased
More informationHexagon PSA. Design Verification. Contents
Design Verification Hexagon PSA Contents 1. Function...2 2. Sensitivity, Dynamic Range and Traceability...2 Description of Control Materials...2 Analytical Sensitivity...2 3. Clinical Evaluation...3 Evaluation
More informationMycoplasma pneumoniae ELISA (recombinant) IgG / IgM Testkit IgA-Set
Mycoplasma pneumoniae ELISA (recombinant) IgG / IgM Testkit IgA-Set Order No.: EC114.00 (IgG/IgM Testkit) Order No.: EC114.08 (IgA-Set) Color Coding: dark blue FOR IN VITRO DIAGNOSIS ONLY Virotech Diagnostics
More informationPneumonia Aetiology Why is it so difficult to distinguish pathogens from innocent bystanders?
Pneumonia Aetiology Why is it so difficult to distinguish pathogens from innocent bystanders? David Murdoch Department of Pathology University of Otago, Christchurch Outline Background Diagnostic challenges
More informationPerformance of Three Microimmunofluorescence Assays for Detection of Chlamydia pneumoniae Immunoglobulin M, G, and A Antibodies
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, July 2002, p. 833 839 Vol. 9, No. 4 1071-412X/02/$04.00 0 DOI: 10.1128/CDLI.09.4.833 839.2002 Copyright 2002, American Society for Microbiology. All Rights
More informationDIAGNOSTIC AUTOMATION, INC.
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationAntiphospholipid Syndrome
Antiphospholipid Syndrome EliA Cardiolipin and EliA β2-glycoprotein I Fully Automated Testing for Antiphospholipid Syndrome (APS) Testing for APS according to classification criteria determination of anti-β2-glycoprotein
More informationThis kit is intended for Research Use Only. Not for use in diagnostic procedures.
This kit is intended for Research Use Only. Not for use in diagnostic procedures. Introduction The DRG Epstein-Barr Virus (VCA) IgM Enzyme Immunoassay Kit provides materials for determination of IgM-class
More informationELISA test to detect Chlamydophila pneumoniae IgG
J. Basic Microbiol. 42 (2002) 1, 13 18 (Departments of Microbiology and Surgery 1, University Hospital San Cecilio, University of Granada, School of Medicine, Granada, Spain) ELISA test to detect Chlamydophila
More informationArbovirus Reports 2015
Arbovirus Reports Arboviruses (Arthropod-borne) are a group of viral infections transmitted by the bite of arthropods, most commonly mosquitoes. Some of these infections are endemic; others may be imported
More informationMicrobiological diagnosis of infective endocarditis; what is new?
Microbiological diagnosis of infective endocarditis; what is new? Dr Amani El Kholy, MD Professor of Clinical Pathology (Microbiology), Faculty of Medicine, Cairo University ESC 2017 1 Objectives Lab Diagnostic
More informationUpper Respiratory Infections. Mehreen Arshad, MD Assistant Professor Pediatric Infectious Diseases Duke University
Upper Respiratory Infections Mehreen Arshad, MD Assistant Professor Pediatric Infectious Diseases Duke University Disclosures None Objectives Know the common age- and season-specific causes of pharyngitis
More informationSee external label 96 tests HSV 2 IgA. Cat #
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationSerological evidence of Legionella species infection in acute exacerbation of COPD
Eur Respir J 2002; 19: 392 397 DOI: 10.1183/09031936.02.00256702 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Serological evidence of Legionella
More informationM. Khanna and S. Visuri
The ProPneumo1 Assay: Detection of Chlamydophila pneumoniae, Mycoplasma pneumoniae, and an Internal Control Using Multiplex PCR on Multiple Real Time PCR Systems S. Dollhopf,, W. Majewski,, P. Douglass,
More informationInfluenza A IgG ELISA
Influenza A IgG ELISA For the qualitative determination of IgG-class antibodies against Influenza A virus in human serum or plasma (citrate, heparin). For Research Use Only. Not For Use In Diagnostic Procedures.
More informationEBV Protocol
EBV Protocol 8.26.14 Data From UNOS Summary Stats 1988-2014 CASU + 2009-2014 CAPC Organ Total PTLD Percent PTLD Percent PTLD in Literature Heart 294 21 7 3-9 Heart-Lung 34 3 9 16 Intestine 42 7 17 10-45
More informationWhat can pediatric MS teach us about adult-onset MS?
What can pediatric MS teach us about adult-onset MS? Emmanuelle Waubant, MD, PhD University of California, San Francisco February 15, 2012 Multiple sclerosis in children Less frequent than in adults Childhood
More informationnr probówki
Name and surname Date Class 1 Topic: Humoral innate immunity 1. Radial immunodiffusion Describe the method Interpret the outcome using the reference tables. mm = g/l (Choose the component: C3 / C4 /C1q)
More informationDr Marie Bruyneel and Deborah Konopnicki. BVIKM/SBMIC November 8th, 2012
Dr Marie Bruyneel and Deborah Konopnicki BVIKM/SBMIC November 8th, 2012 Men, 54 years Emergency room on end october 2009 Sent by his family doctor for Influenza A H1N1? Viral syndrom, cough, fever 39 (7j)
More informationClass 10. DNA viruses. I. Seminar: General properties, pathogenesis and clinial features of DNA viruses from Herpesviridae family
English Division, 6-year programme Class 10 DNA viruses I. Seminar: General properties, pathogenesis and clinial features of DNA viruses from Herpesviridae family II. Assays to be performed: 1. Paul-Bunnel-Davidsohn
More informationEBV-EA IgG. Cat # 1415Z. EBV -EA IgG ELISA. ELISA: Enzyme Linked Immunosorbent Assay. ELISA - Indirect; Antigen Coated Plate
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationELEGANCE Chlamydia pneumoniae IgG ELISA KIT
INTENDED USE The ELEGANCE Chlamydia pneumoniae IgG ELISA has been designed for the in vitro diagnostic measurement of anti- Chlamydia pneumoniae IgG in the screening of human serum. PRINCIPLES OF THE ELEGANCE
More informationChlamydia Trachomatis IgA
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationQUALITY CONTROL for MOLECULAR DIAGNOSTICS Quality issues highlighted through international external quality assessment
QUALITY CONTROL for MOLECULAR DIAGNOSTICS Quality issues highlighted through international external quality assessment William G MacKay PhD Neutral Office Coordinator QCMD The Altum Building, Todd Campus
More informationNursing care for children with respiratory dysfunction
Nursing care for children with respiratory dysfunction 1 Lung Development Specific Immunity to Respiratory Infection Secretory IgA in mucosal immunity IgG in systemic immunity Risk Factors Associated with
More informationMonitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 st January 31 st March 2015
Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 st January 31 st March 2015 1. The cumulative cases report since December 2010 and cases report during January to March 2015 During
More informationLIAISON Measles IgG The fully automated solution for quantitative antibody detection
LIAISON Measles IgG The fully automated solution for quantitative antibody detection FOR OUTSIDE THE US AND CANADA ONLY LIAISON Measles IgG Number of tests 100 Key assay features Method Assay range Solid
More informationAnti-infectious Immunity
Anti-infectious Immunity innate immunity barrier structures Secretory molecules Phagocytes NK cells Anatomical barriers 1. Skin and mucosa barrier 2.hemo-Spinal Fluid barrier 3. placental barrier Phagocytic
More informationPNEUMONIA IN CHILDREN. IAP UG Teaching slides
PNEUMONIA IN CHILDREN 1 INTRODUCTION 156 million new episodes / yr. worldwide 151 million episodes developing world 95% in developing countries 19% of all deaths in children
More informationDetection of Antibodies to Epstein-Barr Virus Capsid Antigen
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1982, p. 69-73 95-1137/82/169-5$2./ Vol. 15, No.1 Detection of Antibodies to Epstein-Barr Virus Capsid Antigen by Immune Adherence Hemagglutination EVELYNE T. LENNETTE,t
More informationELISA. AccuDiag Autoimmune Diseases and Others. ANA Screen Qualitative ~135 min 90.4% 100%
/ AccuDiag Autoimmune Diseases and Others ANA Screen 5102-2 96 ~135 min 90.4% 100% ENA Profile-6 (Sm/RNP, Sm, Jo-1, Scl-70, SS-A, SS-B) 2506-2 96 ~ 60 min 96% 100% ENA Combined Screen (6 antigens) Sm/RNP,
More informationCytomegalovirus, ELISA, Immunofluorescence
Key words: Cytomegalovirus, ELISA, Immunofluorescence Fig. 1 ELISA procedure 250 Đl of well-mixed serum pretreatment was added to each tube (Interfering IgG was removed by pretreating patient's serum).
More informationInnovation in Diagnostics. ToRCH. A complete line of kits for an accurate diagnosis INFECTIOUS ID DISEASES
Innovation in Diagnostics ToRCH A complete line of kits for an accurate diagnosis INFECTIOUS ID DISEASES EN TOXOPLASMOSIS Toxoplasmosis is a parasitic disease caused by with the obligate intracellular
More informationEnzyme Immunoassay (EIA) for the Detection of EB VCA IgG Antibodies in Human Serum. For In Vitro Diagnostic Use Only
EB VCA IgG EIA ID: Black Enzyme Immunoassay (EIA) for the Detection of EB VCA IgG Antibodies in Human Serum. For In Vitro Diagnostic Use Only 25184 96 Tests CONTENTS 1 - INTENDED USE 2 - SUMMARY AND EXPLANATION
More informationKey words: Chlamydia pneumoniae, acute upper resiratory infections, culture, micro-if method
Key words: Chlamydia pneumoniae, acute upper resiratory infections, culture, micro-if method Table 1 Prevalence of antibodies to C. pneumoniae in patients and control group There was no statistically significant
More informationLaboratory diagnosis of congenital infections
Laboratory diagnosis of congenital infections Laboratory diagnosis of HSV Direct staining Tzanck test Immunostaining HSV isolation Serology PCR Tzanck test Cell scrape from base of the lesion smear on
More informationRSV Surveillance in the U.S.
RSV Surveillance in the U.S. Susan I. Gerber, MD Respiratory Virus Program Division of Viral Diseases National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention
More informationSee external label 2 C-8 C 96 tests Chemiluminescence. CMV IgM. Cat # Diluted samples, controls & calibrator 100 µl 30 minutes
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationHuman infection with pandemic (H1N1) 2009 virus: updated interim WHO guidance on global surveillance
Human infection with pandemic (H1N1) 2009 virus: updated interim WHO guidance on global surveillance 10 July 2009 Background This document updates the interim WHO guidance on global surveillance of pandemic
More informationEpstein-Barr Virus (VCA) IgM Human ELISA Kit
ab108732 Epstein-Barr Virus (VCA) IgM Human ELISA Kit Instructions for Use For the qualitative determination of IgM class antibodies against Epstein-Barr Virus in Human serum or plasma (citrate). This
More informationTwo Cases of Acute Respiratory Distress Syndrome with High Values of Chlamydophila pneumoniae-specific Antibodies
CASE REPORT Two Cases of Acute Respiratory Distress Syndrome with High Values of Chlamydophila pneumoniae-specific Antibodies Ryotaro Igusa 1, Atsushi Nakamura 1, Sachiko Kawana 1, Taizou Shibahara 2,
More informationالحترمونا من خري الدعاء
الحترمونا من خري الدعاء Instructions for candidates The examination consists of 30 multiple choice questions, each divided into 5 different parts. Each part contains a statement which could be true or
More information